AU2018351481B2 - Novel artificial nucleic acid molecules - Google Patents

Novel artificial nucleic acid molecules Download PDF

Info

Publication number
AU2018351481B2
AU2018351481B2 AU2018351481A AU2018351481A AU2018351481B2 AU 2018351481 B2 AU2018351481 B2 AU 2018351481B2 AU 2018351481 A AU2018351481 A AU 2018351481A AU 2018351481 A AU2018351481 A AU 2018351481A AU 2018351481 B2 AU2018351481 B2 AU 2018351481B2
Authority
AU
Australia
Prior art keywords
nucleic acid
utr
hsd17b4
atp5a1
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018351481A
Other languages
English (en)
Other versions
AU2018351481A1 (en
Inventor
Frédéric CHEVESSIER-TÜNNESEN
Marion PÖNISCH
Thomas Schlake
Andreas Thess
Moritz THRAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curevac SE
Original Assignee
Curevac SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/057552 external-priority patent/WO2018172556A1/en
Application filed by Curevac SE filed Critical Curevac SE
Publication of AU2018351481A1 publication Critical patent/AU2018351481A1/en
Assigned to CureVac SE reassignment CureVac SE Request for Assignment Assignors: CUREVAC AG
Priority to AU2025200901A priority Critical patent/AU2025200901A1/en
Application granted granted Critical
Publication of AU2018351481B2 publication Critical patent/AU2018351481B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2018351481A 2017-10-19 2018-10-17 Novel artificial nucleic acid molecules Active AU2018351481B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200901A AU2025200901A1 (en) 2017-10-19 2025-02-10 Novel artificial nucleic acid molecules

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/076741 2017-10-19
EPPCT/EP2017/076775 2017-10-19
EP2017076775 2017-10-19
EP2017076741 2017-10-19
AUPCT/EP2018/057552 2018-03-23
PCT/EP2018/057552 WO2018172556A1 (en) 2017-03-24 2018-03-23 Nucleic acids encoding crispr-associated proteins and uses thereof
EP2018076185 2018-09-26
EPPCT/EP2018/076185 2018-09-26
PCT/EP2018/078453 WO2019077001A1 (en) 2017-10-19 2018-10-17 NEW ARTIFICIAL NUCLEIC ACID MOLECULES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200901A Division AU2025200901A1 (en) 2017-10-19 2025-02-10 Novel artificial nucleic acid molecules

Publications (2)

Publication Number Publication Date
AU2018351481A1 AU2018351481A1 (en) 2020-03-12
AU2018351481B2 true AU2018351481B2 (en) 2025-04-03

Family

ID=66173912

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018351481A Active AU2018351481B2 (en) 2017-10-19 2018-10-17 Novel artificial nucleic acid molecules
AU2025200901A Pending AU2025200901A1 (en) 2017-10-19 2025-02-10 Novel artificial nucleic acid molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200901A Pending AU2025200901A1 (en) 2017-10-19 2025-02-10 Novel artificial nucleic acid molecules

Country Status (13)

Country Link
US (1) US20220233568A1 (https=)
EP (1) EP3697912A1 (https=)
JP (3) JP2021501572A (https=)
KR (2) KR20250138817A (https=)
CN (1) CN111630173A (https=)
AU (2) AU2018351481B2 (https=)
BR (1) BR112020004351A2 (https=)
CA (1) CA3073634A1 (https=)
IL (2) IL321714A (https=)
MX (2) MX2020003995A (https=)
RU (1) RU2020115287A (https=)
SG (1) SG11202002186VA (https=)
WO (1) WO2019077001A1 (https=)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
KR102787119B1 (ko) 2015-11-30 2025-03-27 듀크 유니버시티 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
US12612654B2 (en) 2016-02-12 2026-04-28 CureVac SE Method for analyzing RNA
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Ｃｐｆ１に基づくゲノム編集の治療適用
SG11201906297QA (en) 2017-03-24 2019-10-30 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
EP3625363A1 (en) 2017-05-17 2020-03-25 CureVac Real Estate GmbH Method for determining at least one quality parameter of an rna sample
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
CN111511924A (zh) 2017-11-08 2020-08-07 库瑞瓦格股份公司 Rna序列调整
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
CN111511928A (zh) 2017-12-21 2020-08-07 库瑞瓦格股份公司 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
WO2019193183A2 (en) * 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
AU2019254591B2 (en) 2018-04-17 2025-12-11 CureVac SE Novel RSV RNA molecules and compositions for vaccination
WO2020002598A1 (en) 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
SG11202106666UA (en) 2018-12-21 2021-07-29 Curevac Ag Methods for rna analysis
CN110241116B (zh) * 2019-05-21 2023-02-07 中国医学科学院放射医学研究所 一种环状rna及在促进dna损伤修复中的应用
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
CN114502204A (zh) 2019-08-14 2022-05-13 库尔维科公司 具有降低的免疫刺激性质的rna组合和组合物
US20220307017A1 (en) * 2019-08-29 2022-09-29 Universität Zürich Minimal Messenger RNAs and uses thereof
CN110592223B (zh) * 2019-10-31 2022-10-25 中南大学湘雅三医院 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用
CN112759652B (zh) * 2019-11-01 2022-09-20 北京华夏清医治疗科技有限公司 一种嵌合抗原受体及其应用
US12606822B2 (en) * 2019-11-07 2026-04-21 Icahn School Of Medicine At Mount Sinai Synthetic modified RNA and uses thereof
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
KR20220144416A (ko) 2020-02-04 2022-10-26 큐어백 아게 코로나바이러스 백신
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US20230096704A1 (en) * 2020-02-05 2023-03-30 University Of Florida Research Foundation, Incorporated Rna-loaded nanoparticles and use thereof for the treatment of cancer
EP4126030A1 (en) * 2020-04-01 2023-02-08 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticle vaccine against sars-cov-2
CN111413498B (zh) * 2020-04-08 2023-08-04 复旦大学附属中山医院 一种肝细胞肝癌的自身抗体7-AAb检测panel及其应用
CA3170740A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
CN111744019B (zh) * 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
US20220017971A1 (en) * 2020-07-15 2022-01-20 Kookmin University Industry Academy Cooperation Foundation Composition for predicting chemotherapy resistance of ovarian cancer and use thereof
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
US20230279408A1 (en) * 2020-08-07 2023-09-07 The Hong Kong University Of Science And Technology Compositions and methods for increasing protein expression
US20230346921A1 (en) * 2020-08-21 2023-11-02 Peking University Circular rna vaccines and methods of use thereof
EP4157344A2 (en) 2020-08-31 2023-04-05 CureVac SE Multivalent nucleic acid based coronavirus vaccines
US20230383297A1 (en) * 2020-10-09 2023-11-30 Duke University Novel targets for reactivation of prader-willi syndrome-associated genes
CN112280750B (zh) * 2020-10-22 2022-11-01 山东农业大学 具有跨种传播能力的新型鹅星状病毒及其应用
CN112526127B (zh) * 2020-10-28 2022-12-06 四川大学华西医院 一种破伤风抗原的检测方法及其应用
CA3171051A1 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
CN112574997B (zh) * 2021-01-17 2023-07-21 楷拓生物科技(苏州)有限公司 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用
US20240102065A1 (en) 2021-01-27 2024-03-28 CureVac SE Method of reducing the immunostimulatory properties of in vitro transcribed rna
JP2024508707A (ja) * 2021-02-12 2024-02-28 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 熱ショックタンパク質９０結合ドメインを有する活性誘導型融合タンパク質
CA3212653A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
CA3171429A1 (en) 2021-03-31 2022-09-30 Alexander SCHWENGER Syringes containing pharmaceutical compositions comprising rna
CN113341152B (zh) * 2021-04-27 2022-04-26 华南农业大学 Rps9蛋白在食蟹猴超数排卵良好应答预测中的应用
EP4334446A1 (en) 2021-05-03 2024-03-13 CureVac SE Improved nucleic acid sequence for cell type specific expression
US20240342206A1 (en) 2021-07-30 2024-10-17 CureVac SE mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
US20240398933A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
US20240398940A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
CN115029349B (zh) * 2022-06-09 2024-11-12 中国农业大学 与植物抗病性相关的circRNA、来源基因及其应用
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
AU2023310896A1 (en) 2022-07-19 2025-01-30 Shenzhen Shenxin Biotechnology Co., Ltd. Mrna for sars-cov-2 s protein and use thereof
AU2023353931A1 (en) 2022-09-26 2025-03-20 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
CN115606550B (zh) * 2022-10-28 2024-01-12 陆华 一种自身免疫性甲状腺炎诱导的卵巢储备功能低下动物模型的构建方法
CN120112637A (zh) * 2022-11-11 2025-06-06 斯微(上海)生物科技股份有限公司 人工核酸分子
TW202430633A (zh) * 2022-12-07 2024-08-01 科羅拉多大學董事會法人團體 新穎的ｈｉｖ－１變異體及其在動物激發模型中的使用方法
CN120435560A (zh) 2022-12-16 2025-08-05 深圳深信生物科技有限公司 提高rna分子翻译效率和/或稳定性的utr及其应用
EP4660306A1 (en) 2023-01-31 2025-12-10 Synplogen Co., Ltd. Artificially synthesized nucleic acid for increasing protein expression
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
CN116240175B (zh) * 2023-02-28 2024-02-23 武汉科技大学 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024188312A1 (en) * 2023-03-16 2024-09-19 The Hong Kong University Of Science And Technology Compositions and methods for enhanced protein expression
AU2024260120A1 (en) 2023-04-27 2025-11-06 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
AU2024271830A1 (en) * 2023-05-12 2025-11-27 Seqirus Inc. Vaccine adjuvants
EP4713483A1 (en) 2023-05-16 2026-03-25 CureVac RNA Printer GmbH Improved rna in vitro transcription using dna beads
WO2025027060A1 (en) * 2023-07-31 2025-02-06 CureVac SE Nucleic acid encoded runx3 transcription factor
WO2025040263A1 (en) 2023-08-24 2025-02-27 CureVac Manufacturing GmbH Purification process for in vitro amplified dna
JP2025082576A (ja) * 2023-11-17 2025-05-29 アンジェス株式会社 核酸、医薬組成物、及び核酸を製造する方法
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025246436A1 (en) * 2024-05-29 2025-12-04 Therorna Inc. Circular rna-based therapeutic vaccine for treating hpv positive cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013143699A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
WO2013143700A2 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
WO2017036580A1 (en) * 2015-08-28 2017-03-09 Curevac Ag Artificial nucleic acid molecules
WO2018104540A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
WO2018172556A1 (en) * 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN101307095A (zh) 1996-06-14 2008-11-19 明治乳业株式会社 T细胞表位肽
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
EP1246597B1 (en) 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
EP2046954A2 (en) 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
DK2176408T5 (en) 2008-01-31 2015-12-14 Curevac Gmbh Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
EP3269395A1 (en) 2008-11-07 2018-01-17 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
WO2010087791A1 (en) 2009-01-27 2010-08-05 Utc Power Corporation Distributively cooled, integrated water-gas shift reactor and vaporizer
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
SG10201911942UA (en) 2009-05-05 2020-02-27 Muthiah Manoharan Lipid compositions
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US20110250264A1 (en) 2010-04-09 2011-10-13 Pacira Pharmaceuticals, Inc. Method for formulating large diameter synthetic membrane vesicles
KR20190039347A (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
KR101761388B1 (ko) 2010-07-30 2017-07-25 큐어백 아게 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
SI4043040T1 (sl) 2010-08-31 2023-04-28 Glaxosmithkline Biologicals Sa Mali liposomi za dostavo imunogen-kodirajoče RNA
MX2013002332A (es) 2010-08-31 2013-03-18 Novartis Ag Lipidos apropiados para suministro liposomal del arn que codifica la proteina.
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
EP4115875A1 (en) 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
CA2917348A1 (en) 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
RU2016109938A (ru) 2013-08-21 2017-09-26 Куревак Аг Композиция и вакцина для лечения рака предстательной железы
MY174677A (en) 2013-08-21 2020-05-06 Curevac Ag Composition and vaccine for treating lung cancer
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
CN111304231A (zh) * 2013-12-30 2020-06-19 库瑞瓦格股份公司 人工核酸分子
CA2935878C (en) 2014-03-12 2023-05-02 Curevac Ag Combination of vaccination and ox40 agonists
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
PL4023249T3 (pl) * 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
EP3233113A1 (en) 2014-12-16 2017-10-25 CureVac AG Ebolavirus and marburgvirus vaccines
EP3240558A1 (en) * 2014-12-30 2017-11-08 CureVac AG Artificial nucleic acid molecules
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
EP3317424B1 (en) * 2015-07-01 2023-09-06 CureVac Manufacturing GmbH Method for analysis of an rna molecule
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
EP3374504B1 (en) 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
SG10201913630YA (en) 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013143699A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
WO2013143700A2 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
WO2017036580A1 (en) * 2015-08-28 2017-03-09 Curevac Ag Artificial nucleic acid molecules
WO2018104540A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
WO2018172556A1 (en) * 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THESS A ET AL: "Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals", MOLECULAR THERAPY, vol. 23, no. 9, 8 June 2015 (2015-06-08), US, pages 1456 - 1464, *

Also Published As

Publication number Publication date
AU2025200901A1 (en) 2025-02-27
JP2021501572A (ja) 2021-01-21
IL272850A (en) 2020-04-30
RU2020115287A3 (https=) 2022-02-28
KR20200071081A (ko) 2020-06-18
BR112020004351A2 (pt) 2020-09-08
EP3697912A1 (en) 2020-08-26
AU2018351481A1 (en) 2020-03-12
MX2020003995A (es) 2020-07-22
US20220233568A1 (en) 2022-07-28
SG11202002186VA (en) 2020-05-28
WO2019077001A1 (en) 2019-04-25
IL321714A (en) 2025-08-01
CN111630173A (zh) 2020-09-04
JP2024012523A (ja) 2024-01-30
JP2025131658A (ja) 2025-09-09
KR102858623B1 (ko) 2025-09-10
KR20250138817A (ko) 2025-09-22
MX2026002469A (es) 2026-04-01
RU2020115287A (ru) 2021-11-19
CA3073634A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
AU2018351481B2 (en) Novel artificial nucleic acid molecules
KR101343043B1 (ko) 포유동물 내 면역자극성 반응 제공 또는 증강을 위한 노출된 ｍＲＮＡ 및 착화된 (ｍ)ＲＮＡ를 포함하는 조성물 및 이의 용도
KR101513254B1 (ko) 트랜스펙션 및 면역자극을 위한 ｒｎａ 및 양이온성 펩타이드의 복합체
US9616084B2 (en) Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2010088927A1 (en) Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
WO2011069528A1 (en) Lyophilization of nucleic acids in lactate-containing solutions
EP2510100B1 (en) Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CUREVAC SE

Free format text: FORMER APPLICANT(S): CUREVAC AG

FGA Letters patent sealed or granted (standard patent)